134 related articles for article (PubMed ID: 11272601)
21. Detection of cytomegalovirus DNA in sera of liver transplant recipients.
Patel R; Smith TF; Espy M; Wiesner RH; Krom RA; Portela D; Paya CV
J Clin Microbiol; 1994 Jun; 32(6):1431-4. PubMed ID: 8077384
[TBL] [Abstract][Full Text] [Related]
22. Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival.
Bowen EF; Wilson P; Cope A; Sabin C; Griffiths P; Davey C; Johnson M; Emery V
AIDS; 1996 Nov; 10(13):1515-20. PubMed ID: 8931786
[TBL] [Abstract][Full Text] [Related]
23. Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients.
Mengelle C; Rostaing L; Weclawiak H; Rossignol C; Kamar N; Izopet J
J Med Virol; 2015 May; 87(5):836-44. PubMed ID: 25655981
[TBL] [Abstract][Full Text] [Related]
24. A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients.
Madan RP; Campbell AL; Shust GF; Kahn AR; Wistinghausen B; Posada R; Kerkar N; Shneider BL; Emre S; Herold BC
Transplantation; 2009 May; 87(9):1318-24. PubMed ID: 19424031
[TBL] [Abstract][Full Text] [Related]
25. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
Torre-Cisneros J; Caston-Osorio JJ; Martín C; Rivero A; Doblas A; Rojas R; Gómez P; Martínez F; Torres A
Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666
[TBL] [Abstract][Full Text] [Related]
26. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
27. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O
Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744
[TBL] [Abstract][Full Text] [Related]
28. Single tube competitive PCR for quantitation of CMV DNA in the blood of HIV+ and solid organ transplant patients.
Chatellard P; Sahli R; Iten A; von Overbeck J; Meylan PR
J Virol Methods; 1998 Apr; 71(2):137-46. PubMed ID: 9626947
[TBL] [Abstract][Full Text] [Related]
29. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients.
Bhorade SM; Lurain NS; Jordan A; Leischner J; Villanueva J; Durazo R; Creech S; Vigneswaran WT; Garrity ER
J Heart Lung Transplant; 2002 Dec; 21(12):1274-82. PubMed ID: 12490272
[TBL] [Abstract][Full Text] [Related]
30. Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy.
Kim T; Lee YM; Lee SO; Choi SH; Kim YS; Woo JH; Sung H; Jung JH; Shin S; Kim YH; Kang YA; Lee YS; Lee JH; Lee JH; Lee KH; Park SK; Han DJ; Kim SH
Korean J Intern Med; 2016 Sep; 31(5):961-70. PubMed ID: 27055664
[TBL] [Abstract][Full Text] [Related]
31. Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis.
Rasmussen L; Morris S; Zipeto D; Fessel J; Wolitz R; Dowling A; Merigan TC
J Infect Dis; 1995 Jan; 171(1):177-82. PubMed ID: 7798658
[TBL] [Abstract][Full Text] [Related]
32. Lessons from the natural history of cytomegalovirus.
Bowen EF; Griffiths PD; Davey CC; Emery VC; Johnson MA
AIDS; 1996 Nov; 10 Suppl 1():S37-41. PubMed ID: 8970675
[TBL] [Abstract][Full Text] [Related]
33. Qualitative and semiquantitative polymerase chain reaction testing for cytomegalovirus DNA in serum allows prediction of CMV related disease in liver transplant recipients.
Evans PC; Soin A; Wreghitt TG; Alexander GJ
J Clin Pathol; 1998 Dec; 51(12):914-21. PubMed ID: 10070333
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of valganciclovir in the treatment of cytomegalovirus disease in kidney and pancreas transplant recipients.
Luan FL; Chopra P; Park J; Norman S; Cibrik D; Ojo A
Transplant Proc; 2006 Dec; 38(10):3673-5. PubMed ID: 17175363
[TBL] [Abstract][Full Text] [Related]
35. On the edge: measuring CMV viral load.
McGuire S
Posit Aware; 1997; 8(1):16-7. PubMed ID: 11364091
[TBL] [Abstract][Full Text] [Related]
36. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation.
Sia IG; Wilson JA; Groettum CM; Espy MJ; Smith TF; Paya CV
J Infect Dis; 2000 Feb; 181(2):717-20. PubMed ID: 10669361
[TBL] [Abstract][Full Text] [Related]
37. Prevention and treatment of cytomegalovirus infection in organ transplant recipients.
Kusne S; Shapiro R; Fung J
Transpl Infect Dis; 1999 Sep; 1(3):187-203. PubMed ID: 11428989
[TBL] [Abstract][Full Text] [Related]
38. Cytomegalovirus DNA in peripheral blood leukocytes and plasma from bone marrow transplant recipients.
Brytting M; Mousavi-Jazi M; Boström L; Larsson M; Lunderberg J; Ljungman P; Ringdén O; Sundqvist VA
Transplantation; 1995 Nov; 60(9):961-5. PubMed ID: 7491701
[TBL] [Abstract][Full Text] [Related]
39. Quantitation of cytomegalovirus DNA by real-time polymerase chain reaction in peripheral blood specimens of patients with solid organ transplants: comparison with end-point PCR and pp65 antigen test.
Allice T; Enrietto M; Pittaluga F; Varetto S; Franchello A; Marchiaro G; Ghisetti V
J Med Virol; 2006 Jul; 78(7):915-22. PubMed ID: 16721848
[TBL] [Abstract][Full Text] [Related]
40. Prospective, comprehensive, and effective viral monitoring in children undergoing allogeneic hematopoietic stem cell transplantation.
Schönberger S; Meisel R; Adams O; Pufal Y; Laws HJ; Enczmann J; Dilloo D
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1428-35. PubMed ID: 20399877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
